From the Department of Pharmacy, Mission-St. Joseph's Health System, and the University of North Carolina School of Pharmacy Community-Based Practice, Asheville, North Carolina.
Update: Clinically Significant Cytochrome P-450 Drug Interactions
Article first published online: 17 JAN 2012
1998 Pharmacotherapy Publications Inc.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume 18, Issue 1, pages 84–112, January-February 1998
How to Cite
Michalets, E. L. (1998), Update: Clinically Significant Cytochrome P-450 Drug Interactions. Pharmacotherapy, 18: 84–112. doi: 10.1002/j.1875-9114.1998.tb03830.x
- Issue published online: 17 JAN 2012
- Article first published online: 17 JAN 2012
Recent technologies have resulted in an explosion of information concerning the cytochrome P-450 isoenzymes and increased awareness of life-threatening interactions' with such commonly prescribed drugs as cisapride and some antihistamines. Knowledge of the substrates, inhibitors, and inducers of these enzymes assists in predicting clinically significant drug interactions. In addition to inhibition and induction, microsomal drug metabolism is affected by genetic polymorphisms, age, nutrition, hepatic disease, and endogenous chemicals. Of the more than 30 human isoenzymes identified to date, the major ones responsible for drug metabolism include CYP3A4, CYP2D6, CYP1A2, and the CYP2C subfamily.